Cephalon sues Novartis over Nuvigil copy; Merck announces new U.K. management;

> Cephalon has filed a patent-infringement lawsuit to block a Novartis unit from selling a generic version of the narcolepsy drug Nuvigil. Report

> Merck's U.K. business has unveiled its new leadership team, following last year's merger with Schering-Plough. Report

> Abbott Laboratories has sued Teva Pharmaceutical Industries over an alleged patent violation on its Simcor cholesterol med. Report

> Amgen posted a 1 percent increase in fourth-quarter profits, with sales of its anemia drugs holding steady overall. Report

> Perrigo, a maker of prescription drugs and store-brand medications, hit a 52-week high last week and is likely to outperform benchmarks in 2010, The Street forecasts. Report

> Sanofi-Aventis says it has obtained U.S. antitrust clearance for its purchase of Chattem. Report

Biotech News

> The CEO of Belgium's Galapagos says that the biotech company is planning an important strategic shift, risking its money on solo drug development projects focused on rare diseases. Story

> Jupiter, FL-based Envoy Therapeutics says it has struck a multi-year research collaboration deal with an affiliate of Merck to discover novel diabetes and obesity drug targets. Report

> Over the past few years resveratrol has emerged as one of the most closely-tracked development programs in biotechnology. But now a team of scientists at Pfizer has published new research that Forbes writer Matthew Herper claims casts considerable doubts on resveratrol's potential. Story

> Shares of Dynavax Technologies spiked 30 percent this morning after the developer announced that two early stage trials of its experimental hepatitis C drug SD-101 showed the therapy appeared safe as it spurred anti-viral activity. Report

> After an exhaustive 21-month review, the FDA has extended its approval for the blockbuster new type 2 diabetes drug Victoza (liraglutide). Story

Biotech Research News

> The Burnham Institute for Medical Research has a big new supporter and a new name. South Dakota philanthropist T. Denny Sanford is giving the institute $50 million. Item

> John Tierney at the New York Times writes that the fierce debate over the corrupting influence of corporate money in scientific research has become a fetish that is pushing some of the country's top researchers to stop accepting any support from drug companies. Story

> A group of engineers at the University of Florida used technology employed to mass manufacture cell phones and other devices to make a small sensor that could be used to monitor a person's health, flagging changes in glucose levels or checking for signs of breast cancer. Report

> Scientists at Weill Cornell Medical College have developed a new method to harvest a rich source of endothelial cells which could then be used to create new blood vessels or help regenerate organs damaged by a heart attack or stroke. Item

> Boston-area researchers have discovered the reason why some breast cancer patients respond to normal chemotherapy but others do not. Story

> A team of scientists drawn from the University of Central Florida and Louisiana State University has identified the mechanics at work during a stroke that causes cell death and spurs severe brain damage. Report

> A Stanford team has identified a key protein that could herald a new class of hepatitis C drugs. And the lead author of the study says that a new therapy could be in the clinic in as a little as 18 months. Story

And Finally... Controlling blood pressure just might be the best protection yet against dementia. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.